Search results
Showing 106 to 120 of 179 results for transplantation
Improving consent rates:- What are the key components of an intervention to improve consent rates?
guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...
guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...
Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia. This involves using heat to destroy selected areas of the heart to prevent the occurrence or conduction of abnormal electrical activity.
View recommendations for IPG295Show all sections
Sections for IPG295
Evidence-based recommendations on robot-assisted kidney transplant in adults. This involves the surgeon using a robot to help with a kidney transplant.
View recommendations for IPG609Show all sections
This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.
View quality statements for QS79Show all sections
Sections for QS79
- Quality statements
- Quality statement 1: Diagnosis of idiopathic pulmonary fibrosis
- Quality statement 2: Access to a specialist nurse
- Quality statement 3: Assessment for oxygen therapy
- Quality statement 4: Pulmonary rehabilitation
- Quality statement 5: Palliative care
- Update information
- About this quality standard
Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.
View recommendations for IPG691Show all sections
Reasons for refusal for consent:- Why do families refuse to give permission for organ donation?
guidance details Comes from guidance Organ donation for transplantation: improving donor identification and consent rates for deceased...
Extracorporeal albumin dialysis for acute liver failure (IPG316)
Evidence-based recommendations on extracorporeal albumin dialysis for acute liver failure. This involves using a dialysis machine to remove both water-soluble toxins and toxins that are attached to albumin and accumulate in liver failure.
View recommendations for IPG316Show all sections
Sections for IPG316
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Laser correction of refractive error following non-refractive ophthalmic surgery (IPG385)
Evidence-based recommendations on laser correction of refractive error following non-refractive ophthalmic surgery. This involves changing the shape of the cornea, so that light rays are more precisely directed onto the retina.
View recommendations for IPG385Show all sections
Sections for IPG385
Boston Keratoprosthesis Type I for corneal blindness (MIB91)
NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .
treatment with, for example, high-dose therapy and autologous stem cell transplantation. Many factors are likely to influence outcome,...
occur spontaneously or arise during immunosuppression. Solid organ transplantation, chemotherapy and immunosuppressive drugs used to...
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Immunosuppressive therapy for kidney transplant in children and young people (TA482)
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in children and young people. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).